Publication date: Jul 10, 2019
To pursue this possibility of remote monitoring, a group of researchers and physicians at the University of Texas at Tyler and the University of Massachusetts, Medical School have been investigating using a wearable biosensor to monitor treatment adherence in substance use disorder patients.
The research group utilized the E4 wristband wearable biosensor from Empatica, the same company that makes the Embrace2 Watch, a wearable biosensor for detecting epilepsy in children.
In this study, the research group use the sensor capabilities of the E4 to collect data on active drug users, then applied machine learning techniques to develop predictors for non-adherence of treatment regimens.
Their earliest study dates back to 2015 in which they employed the Q Sensor, the now-discontinued predecessor of the E4 wearable, to monitor changes in electrodermal activity, skin temperature, and locomotion.
In their 2018 study, titled -Automatic Detection of Opioid Intake Using Wearable Biosensor”, they improved upon their 2015 paper by utilizing machine learning and pattern recognition to automatically differentiate baseline readings of different physiological signals from abnormal readings elicited by substance use.
Maxim Integrated has been placing emphasis on healthcare applications in many of the hardware components and tools they release, including a wearable platform for remote biometric monitoring for developers.
- The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies.
- Hospital-based pharmacists spearhead opioid stewardship
- Governments use cloud technology to combat opioid crisis